药物信息为Optiray 350 (Mallinckrodt Inc.): CT SCANNING OF THE HEAD
- WARNING
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- CT SCANNING OF THE HEAD
- CT SCANNING OF THE BODY
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- ADVERSE REACTIONS
- OVERDOSAGE
- INDIVIDUAL INDICATIONS, USAGE AND PROCEDURAL INFORMATION GENERAL ANGIOGRAPHY
- COMPUTED TOMOGRAPHY
- INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
- HOW SUPPLIED
- RFID-Tagged Syringe Directions for Use
- 外部链接相关的Optiray 350 (Mallinckrodt Inc.)
In contrast enhanced computed tomographic head imaging, OPTIRAY does not accumulate in normal brain tissue due to the presence of the normal blood-brain barrier. The increase in x-ray absorption in the normal brain is due to the presence of contrast agent within the blood pool. A break in the blood-brain barrier such as occurs in malignant tumors of the brain allows for the accumulation of contrast medium within the interstitial tissue of the tumor. Adjacent normal brain tissue does not contain the contrast medium.
Maximum contrast enhancement in tissue frequently occurs after peak blood iodine levels are reached. A delay in maximum contrast enhancement can occur. Diagnostic contrast enhanced images of the brain have been obtained up to 1 hour after intravenous bolus administration. This delay suggests that radiographic contrast enhancement is at least in part dependent on the accumulation of iodine containing medium within the lesion and outside the blood pool, although the mechanism by which this occurs is not clear. The radiographic enhancement of nontumoral lesions, such as arteriovenous malformations and aneurysms, is probably dependent on the iodine content of the circulating blood pool.
In patients where the blood-brain barrier is known or suspected to be disrupted, the use of any radiographic contrast medium must be assessed on an individual risk to benefit basis. However, compared to ionic media, nonionic media are less toxic to the central nervous system.
- Drug Information Provided by National Library of Medicine (NLM).
